An interventional study of Metabolic response to protein source in Polycystic Ovary Syndrome (PCOS), sponsored by University of Arkansas, Fayetteville. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by University of Arkansas, Fayetteville · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.
Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 88th largest by planned enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2025, is one of 74 with no phase, reaches primary completion later than 24 of the 41 other live ones, and was the 175th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18–40 · Women only
University of Chicago · Sites in United States
Ages 18–40 · Women only
Texas A&M University · Sites in United States
Ages 11–17 · Women only
University of Wisconsin, Madison · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 8+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 20 · Phase 3 16 · Phase 4 14
First in 1997; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 39 across the 146 interventional studies, 65 across the 35 observational. Of the 122 that completed or were terminated, 57 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 183 have an industry lead sponsor. The 10 most frequent:
University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 7 are open to participants now.
University of Arkansas, Fayetteville has 2 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Polycystic Ovary Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04407754University of OklahomaMyo-Inositol for Infertility in PCOS | 2026-12 |
| NCT07227363Ohio State UniversitySymptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot | 2026-12 |
| NCT07392476The Cleveland ClinicContinuous Glucose Monitoring in Polycystic Ovarian Syndrome | 2026-12-31 |
| NCT07142603University of Arkansas, FayettevilleAppetite Response to Meals With Different Protein Sources in Women With PCOS | 2026-12-31 |
| NCT07571915The Cleveland ClinicHealth-Related Quality of Life and Metabolic Outcomes in PCOS | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that improve postprandial insulin and glucose responses are central to managing metabolic symptoms in PCOS.
Meals higher in protein can attenuate postprandial glycemia and enhance satiety, but the effects may vary by protein source. Animal sources of protein typically have higher essential amino acid content and insulinogenic potential, whereas plant proteins offer fiber and phytochemicals that may influence glycemic dynamics differently. Few studies have directly compared the acute metabolic effects of plant versus animal protein in women with PCOS. Given the distinct pathophysiology of PCOS, extrapolating findings from healthy populations may be misleading.
Understanding protein-specific effects on postprandial insulin, glucose, and appetite-regulating hormones in this group is essential for targeted nutrition guidance. Additionally, plant-based diets are increasingly promoted for cardiometabolic health, but their acute effects in insulin-resistant women remain underexplored. This study will assess whether plant and animal protein meals elicit differential postprandial responses in women with PCOS. Findings may inform dietary recommendations aimed at improving metabolic outcomes in this high-risk population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After an overnight fast, participants will be given a 350-400 kcal meal containing 30% energy from plant protein sources. Participants will be given 10 minutes to consume the meal and appetite and metabolic response will be measured for 240 following the meal.
Other: Metabolic response to protein source
After an overnight fast, participants will be given a 350-400 kcal meal containing 30% energy from animal protein sources. Participants will be given 10 minutes to consume the meal and appetite and metabolic response will be measured for 240 following the meal.
Other: Metabolic response to protein source
Participants will be given a 350-400 kcal meal challenge containing 30% energy from animal protein. They will be given 10 minutes to consume the meal and meal response will be measured 240 minutes following the meal.
Energy expenditure
Energy expenditure will be measured using indirect calorimetry.
Time frame: Meal response over 240 minutes (0, 30, 60, 120, 180, and 240 minutes post meal challenge).
Appetite
Participants will be asked to rate their perceived hunger, fullness, and desire to eat with the use of a traditional 100 mm visual analog scales (VAS) with opposing anchors (e.g., "extremely hungry" or "not hungry at all"). The questions include "how hungry do you feel at this moment," "how full do you feel at this moment," "how strong is your desire to eat at this moment," and "how much food do you think you could eat at this moment." Participants will also be asked to evaluate the appearance ("how much do you like or dislike the appearance of the breakfast foods") and palatability ("how much do you like or dislike the smell and taste of the breakfast foods") of the breakfast with the use of a traditional 100 mm visual analog scale with opposing anchors "dislike extremely" or "like extremely." Appetite assessments were measured at 0, 15, 30, 60, 120, and 240 min after the meal.
Time frame: Meal response over 240 minutes (0, 30, 60, 120, 180, and 240 minutes post meal challenge).
Plasma amino acid response
Plasma amino acids will be measured using UPLC
Time frame: Meal response over 240 minutes (0, 30, 60, 120, 180, and 240 minutes post meal challenge).
Plasma biomarkers related to appetite
Appetite biomarkers including PYY (Peptide YY), CCK (cholecystokinin), BDNF (brain-derived neurotrophic factor), GLP-1 (glucagon-like petide-1), and ghrelin will be measured using commercially available kits. This measurements will be interpreted together to make a conclusion about a appetite regulation in response to protein source.
Time frame: Meal response over 240 minutes (0, 30, 60, 120, 180, and 240 minutes post meal challenge).
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Arkansas, Fayetteville